Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001610618-25-000068
Filing Date
2025-06-18
Accepted
2025-06-18 17:05:35
Documents
1
Period of Report
2025-06-18

Document Format Files

Seq Description Document Type Size
1 FORM 4 wk-form4_1750280729.html 4  
1 FORM 4 wk-form4_1750280729.xml 4 3870
  Complete submission text file 0001610618-25-000068.txt   5482
Mailing Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121
Business Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121 858-752-6170
Cidara Therapeutics, Inc. (Issuer) CIK: 0001610618 (see all company filings)

EIN.: 461537286 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O DYNAVAX TECHNOLOGIES CORPORATION 2100 POWELL STREET, SUITE 720 EMERYVILLE CA 94608
Business Address
Spencer Ryan (Reporting) CIK: 0001777938 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-36912 | Film No.: 251057718